Frequency Therapeutics Supports HLAA Meeting on SNHL

Frequency Therapeutics, Inc, (Nasdaq: FREQ) shared a statement from David L. Lucchino, Frequency’s Chief Executive Officer, in support of the Hearing Loss Association of America (HLAA) and its efforts to advance the voice of the patient in leading “the first-ever Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting on sensorineural hearing loss (SNHL).”